http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020123200-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af1f8003c81cf172ed5f1bdd067371ce
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
filingDate 2018-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d532a2049de2020c60abdd34172ab295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a57d934b8714da9ea45b17edea2e2a62
publicationDate 2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2020123200-A1
titleOfInvention Treatment of haematological malignancies
abstract Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ΔNPM 1 positive haematological malignancy. Corresponding methods and uses are also provided.
priorityDate 2017-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399383
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399382
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6106
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395314
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395986
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395985
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395485
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID994
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1148
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395486
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398740
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398728
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID857
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6306
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6305
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID791

Total number of triples: 57.